Cardiovascular Systems (NASDAQ: CSII) and Globus Medical (NYSE:GMED) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.
Valuation and Earnings
This table compares Cardiovascular Systems and Globus Medical’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cardiovascular Systems||$204.91 million||4.12||-$1.79 million||($0.10)||-254.00|
|Globus Medical||$635.98 million||7.80||$107.34 million||$1.21||42.55|
Risk & Volatility
Cardiovascular Systems has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
Insider & Institutional Ownership
82.6% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 65.9% of Globus Medical shares are owned by institutional investors. 3.3% of Cardiovascular Systems shares are owned by insiders. Comparatively, 28.2% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Cardiovascular Systems and Globus Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Cardiovascular Systems and Globus Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cardiovascular Systems currently has a consensus price target of $26.50, indicating a potential upside of 4.33%. Globus Medical has a consensus price target of $48.83, indicating a potential downside of 5.16%. Given Cardiovascular Systems’ higher possible upside, research analysts clearly believe Cardiovascular Systems is more favorable than Globus Medical.
Globus Medical beats Cardiovascular Systems on 11 of the 14 factors compared between the two stocks.
About Cardiovascular Systems
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
About Globus Medical
Globus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company sells its products through exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.